Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma

Summary

This study is being conducted to evaluate the safety profile and the Maximum Tolerated Dose (MTD) of TAK-901 in adult patients with advanced solid tumors or lymphoma. This study will help to identify the recommended phase 2 dose and infusion duration, and describe the pharmacokinetics of TAK-901.

Timeline

Start

2009-10

Primary completion

2011-08

Completion

2011-11

Drugs

Indications